/stocks — the workspaceLOADING
All DMAAU SEC filings, by type → · Earnings date & implied move · Search inside filings
Drugs Made In America Acquisition Corp. (DMAAU) is a blank checks company. Fundamentals from SEC filings; prices are end-of-day.
What’s behind DMAAU’s latest move — the size, how unusual the volume is, and the catalyst on the tape, explained and cited to the source.
End-of-day bars · delayed, not real-time · data: Databento · studies computed in your browser from these barsCharting by TradingView Lightweight Charts™
XBRL company facts, SEC EDGAR. TTM = last four reported quarters. Valuation ratios arrive with a price source — we don't fake quotes.
Not reported in XBRL for this filer.
Not reported in XBRL for this filer.
↓ Download the fiscal-year statement table: XLSX · CSV · revenue, income, EPS, cash flow, balance sheet · from SEC XBRL, dated
As filed. We do not recategorize line items. Each chart plots one XBRL concept exactly as DMAAU tagged it: net income us-gaap:NetIncomeLoss, period by period; a period the company did not tag on its own is left out, not estimated. A figure that disagrees with the filing is a bug in our extraction, not a policy, and we fix it: report a mismatch.
A plain-English read on DMAAU plus an auto-SWOT — built from DMAAU's SEC filings and market data, every point cited, nothing invented. Educational, not investment advice.
Four AI analysts — a bull, a bear, a risk manager, and a PM — debate DMAAU using only the SEC-filing and market facts below. Every point cites its evidence; nothing is invented. This is educational research, not investment advice.
Educational only — not financial advice. Data from SEC EDGAR public filings; no live market data is shown. Figures reflect the company's own reported XBRL facts and may lag.
Has DMAAU been issuing shares? Offering history →
Projected from DMAAU's own SEC 8-K filing history — the year-over-year reporting pattern (about 47% land the exact day, about 91% within a week, measured across 4,713 past reports). No analyst estimates and nothing invented, and every confirmed date links to the source it came from, so you can check it yourself. It upgrades the momentDMAAU files or announces.
Earnings dates are the company's 8-K Item 2.02 filings (SEC). Reactions from Databento EOD.
None of the 5 estimators could run on DMAAU's filings.
One estimator is a point estimate, not a range, so no band and no valuation label are published for DMAAU. Below is everything that was checked, so the refusal can be read rather than taken on trust.
Nothing produced a value.
No fiscal year of price history was on record; the historical multiples need 5. No sector peer set is priced for DMAAU, so sector medians could not fill the gaps.
Every refusal recorded for DMAAU → · How often we decline, and why →
No lawmaker has disclosed a trade in DMAAU under the STOCK Act.
No tracked institution reported a position in DMAAU in the latest 13F round.
No open-market Form 4 buys or sells reported for DMAAU in the last ~6 months.
2 of the 2 checks that ran found nothing new for DMAAU. 2 could not run.
Each event check looks back 30 days from the date its own source was stored, read or generated, never from the date this page was built. A check that finds nothing is a measurement of that window, not a forecast, and a check that cannot be dated does not make the claim at all.
Head office: New York, New York, United States · the company’s charter and its head office are in different countries.
Source: the cover page of Drugs Made In America Acquisition Corp.’s 10-Q filed 2026-08-14, on EDGAR. Filings checked 2026-10-25. Incorporation is where the company’s charter was filed. It is not where the business operates or earns, which no filing cover states. How this works